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Objective 
Determine long term survival among 
women treated for cervical cancer, with 
outcomes available up to 48 years 
following diagnosis, to provide long-term 
information regarding mortality and 
morbidity following treatment. 
Methods 
Retrospective chart review of 356 
women aged 15-35 years treated for 
cervical cancer between 1960 and 1987 
at a single institution with outcomes 
available through March 2008. 
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Results 
The mean age at diagnosis was 29.8 
years; 95% were white, 89% were 
parous, 52% had a history of hormone 
use including oral contraceptives, 13% 
had been treated for an STI, 50% 
reported tobacco use, 71% had never 
had an abnormal Pap smear, Pap 
smear finding prior to diagnosis of 
cancer was low grade dysplasia in 56%, 
94% did not have a family history of 
cervical cancer. Histology was 
squamous cell in 85% and 
adenocarcinoma in 12%. FIGO clinical 
stage revealed: 54.2% Stage I, 6.7% 
Stage II, 3.4% Stage 3, 1.1% Stage 4, 
and 34.6% un-staged. 
As expected, long-term survival and 
cancer recurrence was associated with 
initial cancer staging. 87 (24%) of 
women were determined to have 
recurrent disease with a mean age of 
Proceedings in Obstetrics and Gynecology, 2011 July; 2(1):13 
 
Long-Term Outcomes in Women Treated for Cervical Cancer  2 
 
recurrence of 32 years. Among women 
with Stage IA disease there was one 
recurrence, while all women with Stage 
III disease had at least one recurrence. 
No woman with stage IV disease 
survived beyond the initial treatment 
period. 157 (44%) of women had 
passed away by May 2008, of which 
74% deaths were from primary or 
recurrent cancer. Mean age of death 
was age 47 years. No variables were 
identified which impacted the duration of 
survival or risk for cancer recurrence 
beyond clinical stage of cancer. 
Conclusion 
Among a cohort of young women 
treated for cervical cancer over a 27 
year period, with survival available up to 
48 years from initial diagnosis, there 
were no variables identified which 
impacted the duration of survival beyond 
the initial stage of cervical cancer at 
presentation. 
